143 related articles for article (PubMed ID: 32020229)
1. Cyclin F is involved in response to cisplatin treatment in melanoma cell lines.
Krajewski A; Gagat M; Żuryń A; Hałas-Wiśniewska M; Grzanka D; Grzanka A
Oncol Rep; 2020 Mar; 43(3):765-772. PubMed ID: 32020229
[TBL] [Abstract][Full Text] [Related]
2. Potential role of cyclin F mRNA expression in the survival of skin melanoma patients: Comprehensive analysis of the pathways altered due to cyclin F upregulation.
Gagat M; Krajewski A; Grzanka D; Grzanka A
Oncol Rep; 2018 Jul; 40(1):123-144. PubMed ID: 29767233
[TBL] [Abstract][Full Text] [Related]
3. A cyclin without cyclin-dependent kinases: cyclin F controls genome stability through ubiquitin-mediated proteolysis.
D'Angiolella V; Esencay M; Pagano M
Trends Cell Biol; 2013 Mar; 23(3):135-40. PubMed ID: 23182110
[TBL] [Abstract][Full Text] [Related]
4. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair.
D'Angiolella V; Donato V; Forrester FM; Jeong YT; Pellacani C; Kudo Y; Saraf A; Florens L; Washburn MP; Pagano M
Cell; 2012 May; 149(5):1023-34. PubMed ID: 22632967
[TBL] [Abstract][Full Text] [Related]
5. Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.
Zhang M; Wang J; Yao R; Wang L
Int J Gynecol Cancer; 2013 May; 23(4):659-66. PubMed ID: 23466567
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-21 antisense oligonucleotide improves the sensitivity of A375 human melanoma cell to Cisplatin: An in vitro study.
Zhang HL; Si LB; Zeng A; Long F; Qi Z; Zhao R; Bai M
J Cell Biochem; 2018 Apr; 119(4):3129-3141. PubMed ID: 29058784
[TBL] [Abstract][Full Text] [Related]
7. Cyclin F/FBXO1 Interacts with HIV-1 Viral Infectivity Factor (Vif) and Restricts Progeny Virion Infectivity by Ubiquitination and Proteasomal Degradation of Vif Protein through SCF
Augustine T; Chaudhary P; Gupta K; Islam S; Ghosh P; Santra MK; Mitra D
J Biol Chem; 2017 Mar; 292(13):5349-5363. PubMed ID: 28184007
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of GADD45A enhances chemosensitivity in melanoma.
Liu J; Jiang G; Mao P; Zhang J; Zhang L; Liu L; Wang J; Owusu L; Ren B; Tang Y; Li W
Sci Rep; 2018 Mar; 8(1):4111. PubMed ID: 29515153
[TBL] [Abstract][Full Text] [Related]
9. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
Yang X; Yang Y; Tang S; Tang H; Yang G; Xu Q; Wu J
J Pharmacol Sci; 2015 Sep; 129(1):65-71. PubMed ID: 26390965
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide screening identifies novel genes and biological processes implicated in cisplatin resistance.
Ko T; Li S
FASEB J; 2019 Jun; 33(6):7143-7154. PubMed ID: 30844312
[TBL] [Abstract][Full Text] [Related]
11. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
[TBL] [Abstract][Full Text] [Related]
12. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
[TBL] [Abstract][Full Text] [Related]
13. Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma.
Fatkhutdinov N; Sproesser K; Krepler C; Liu Q; Brafford PA; Herlyn M; Aird KM; Zhang R
Mol Cancer Res; 2016 Sep; 14(9):767-75. PubMed ID: 27297629
[TBL] [Abstract][Full Text] [Related]
14. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
[TBL] [Abstract][Full Text] [Related]
15. SiRNA-Mediated
Xue T; Wang L; Li Y; Song H; Chu H; Yang H; Guo A; Jiao J
Int J Med Sci; 2019; 16(11):1510-1516. PubMed ID: 31673243
[No Abstract] [Full Text] [Related]
16. Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity.
Kuo ML; Hwang HS; Sosnay PR; Kunugi KA; Kinsella TJ
Cancer J; 2003; 9(4):277-85. PubMed ID: 12967138
[TBL] [Abstract][Full Text] [Related]
17. Cyclin F Downregulation Affects Epithelial-Mesenchymal Transition Increasing Proliferation and Migration of the A-375 Melanoma Cell Line.
Krajewski A; Gagat M; Mikołajczyk K; Izdebska M; Żuryń A; Grzanka A
Cancer Manag Res; 2020; 12():13085-13097. PubMed ID: 33376401
[TBL] [Abstract][Full Text] [Related]
18. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.
Sun X; Shi B; Zheng H; Min L; Yang J; Li X; Liao X; Huang W; Zhang M; Xu S; Zhu Z; Cui H; Liu X
Cell Death Dis; 2018 Feb; 9(3):260. PubMed ID: 29449532
[TBL] [Abstract][Full Text] [Related]
19. Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism.
Karwaciak I; Sałkowska A; Karaś K; Dastych J; Ratajewski M
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34068624
[TBL] [Abstract][Full Text] [Related]
20. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line.
Hochhauser D; Schnieders B; Ercikan-Abali E; Gorlick R; Muise-Helmericks R; Li WW; Fan J; Banerjee D; Bertino JR
J Natl Cancer Inst; 1996 Sep; 88(18):1269-75. PubMed ID: 8797766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
